



GlaxoSmithKline

5 Moore Drive
P.O. Box 13398
Research Triangle Park, NC
27709-3398

www.gsk.com

May 3, 2013

Jon Jureidini, MB, PhD
The University of Adelaide
Department of Psychological Medicine
Women's and Children's Hospital
North Adelaide, 5006, South Australia

Dear Dr. Jureidini:

I am responding to your letter addressed to Andrew Witty dated April 26, 2013, regarding an article published in the July 2001 issue of The Journal of the American Academy of Child and Adolescent Psychiatry ("JAACAP") on Paroxetine Study 329 entitled, "Efficacy of Paroxetine in the Treatment of Adolescent Major Depression: A Randomized, Controlled Trial."

GSK does not agree that the article is false, fraudulent or misleading. The article, which was subjected to peer review on three occasions prior to publication, accurately reflects the honestly-held views of the clinical investigator authors. It is my understanding that you recently requested both Brown University and JAACAP retract the article and that both Brown and JAACAP declined to do so. Indeed, according to an e-mail from Dr. Andres Martin, Editor-in-Chief of JAACAP, to you that was apparently sent December 21, 2012 and reprinted in a post by Ed Silverman on January 9, 2013 on www.pharmalot.com, "Journal Refuses to Retract Controversial Paxil Study," in response to your request, the JAACAP editorial board undertook a "comprehensive and extensive review" and "found no basis for retraction or other editorial action."

In light of the above, GSK does not believe it appropriate to request retraction of the article.

Very truly yours,

A handwritten signature in black ink, appearing to read "John E. Kraus", written over a horizontal line.

John E. Kraus, MD, PhD, DFAPA
Head of Medical Governance
Neurosciences Therapy Area Unit
GlaxoSmithKline Research & Development